Sulfasalazine-Induced Epstein-Barr Virus-Positive Mucocutaneous Ulcer
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Epstein-Barr virus (EBV) may cause a wide spectrum of symptomatology in humans ranging from asymptomatic upper respiratory tract infection to infectious mononucleosis and in more severe cases lymphoproliferative disorders or hemophagocytic lymphohistiocytosis. Its neoplastic potential is higher in immunocompromised individuals. We describe a case of EBV-positive mucocutaneous ulcer, a more indolent clinical entity on the spectrum of EBV-driven lymphoproliferative disorders, and are one of the first to put sulfasalazine, an immunomodulatory agent, forward as the possible culprit.
References
1.
Prieto-Torres L, Erana I, Gil-Redondo R, Gomez de la Riva I, Manso R, Pajares R
. The Spectrum of EBV-Positive Mucocutaneous Ulcer: A Study of 9 Cases. Am J Surg Pathol. 2018; 43(2):201-210.
DOI: 10.1097/PAS.0000000000001186.
View
2.
Yoshinaga N, Oka S, Asagoe K
. [Regression of diffuse large B-cell lymphoma after discontinuation of salazosulfapyridine]. Rinsho Ketsueki. 2022; 63(2):99-103.
DOI: 10.11406/rinketsu.63.99.
View
3.
Montes L, Tredez E, Yzet C, Delette C, Chatelain D, Lebon D
. Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30. Clin Case Rep. 2020; 8(6):958-961.
PMC: 7303872.
DOI: 10.1002/ccr3.2721.
View
4.
Roberts T, Chen X, Liao J
. Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. Exp Hematol Oncol. 2016; 5:13.
PMC: 4848873.
DOI: 10.1186/s40164-016-0042-5.
View
5.
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow S
. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019; 133(16):1703-1714.
PMC: 6473500.
DOI: 10.1182/blood-2018-11-881268.
View